Caribou Biosciences, Inc.
CRBUNasdaq
$1.65
↓ -0.6%Jul 17 close · end-of-day
Price
1Y↓ -9.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$158.2M
Enterprise Value
$40.5M
P/E
—
P/S
14.1
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
-64.3%
Dividend Yield
—
Revenue (TTM)
$11.2M
Net Income (TTM)
-$133.2M
Free Cash Flow (TTM)
-$101.6M
Gross Margin
—
Operating Margin
-1175.7%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$117.6M
Return 1Y
-9.8%
Company profile
Caribou Biosciences, Inc. engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010 and CB-011, which are in phase 1 clinical trials to treat relapsed or refractory B cell non-Hodgkin lymphoma.
- CEO
- Rachel E. Haurwitz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- California
- Website
- cariboubio.com
Management & directors
- Kelly Timothy PChief Technology Officer
- Albertson Tina M.Chief Medical Officer
- Khan Ruhi AhmadChief Business Officer
- Mcclung Barbara GChief Legal Officer
- Haurwitz Rachel E.President and CEO
- Ryali SriramChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CRBU Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.4M↑ +1.9%
Diluted EPS-$0.26↓ -39.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $12.4M | $9.6M | $13.9M | $34.5M | $10.0M | $11.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$36.1M | -$67.0M | -$106.4M | -$116.1M | -$166.6M | -$148.3M |
| Net income | -$34.3M | -$66.9M | -$99.4M | -$102.1M | -$149.1M | -$148.1M |
| Diluted EPS | — | -$2.11 | -$1.64 | -$1.38 | -$1.65 | -$1.59 |
| Operating cash flow | -$33.2M | -$32.5M | -$91.0M | -$93.3M | -$138.2M | -$111.0M |
| Free cash flow | -$33.5M | -$34.6M | -$97.4M | -$104.9M | -$143.1M | -$112.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -292.2% | -697.8% | -768.2% | -336.6% | -1667.2% | -1329.4% |
| Net margin | -277.6% | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $2.0M | $2.1M | $2.4M | $2.7M | $2.2M | $3.9M | $2.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$43.5M | -$38.2M | -$38.9M | -$42.9M | -$47.6M | -$29.4M | -$28.5M | -$26.3M |
| Net income | -$37.7M | -$34.7M | -$35.5M | -$40.0M | -$54.1M | -$27.5M | -$26.5M | -$25.1M |
| Diluted EPS | -$0.42 | -$0.38 | -$0.39 | -$0.43 | -$0.58 | -$0.30 | -$0.28 | -$0.26 |
| Operating cash flow | -$32.9M | -$32.7M | -$35.5M | -$36.7M | -$28.3M | -$25.2M | -$20.8M | -$27.0M |
| Free cash flow | -$35.1M | -$33.3M | -$36.0M | -$37.8M | -$28.7M | -$25.3M | -$21.0M | -$27.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1255.8% | -1889.2% | -1871.7% | -1823.8% | -1784.0% | -1337.6% | -722.0% | -1096.4% |
| Net margin | -1088.3% | -1713.6% | -1708.7% | -1699.6% | -2028.4% | -1253.3% | -672.1% | -1046.5% |
Company news
Jun 11, 2026
Jun 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-25 | Kelly Timothy P· Chief Technology Officer | Sale | 6,228 | $1.93 | $12,020.04 | filing |
| 2026-02-24 | MCCLUNG BARBARA G· Chief Legal Officer | Sale | 6,938 | $1.96 | $13,598.48 | filing |
| 2026-02-24 | Khan Ruhi Ahmad· Chief Business Officer | Sale | 6,938 | $1.96 | $13,598.48 | filing |
| 2026-02-24 | Kelly Timothy P· Chief Technology Officer | Sale | 3,147 | $1.96 | $6,168.12 | filing |
| 2026-02-24 | Albertson Tina M.· Chief Medical Officer | Sale | 1,066 | $1.96 | $2,089.36 | filing |
| 2026-02-20 | Ryali Sriram· Chief Financial Officer | Award | 55,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Haurwitz Rachel E.· President and CEO | Award | 151,700 | $0.00 | $0.00 | filing |
| 2026-02-20 | Kelly Timothy P· Chief Technology Officer | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | MCCLUNG BARBARA G· Chief Legal Officer | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Khan Ruhi Ahmad· Chief Business Officer | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Albertson Tina M.· Chief Medical Officer | Award | 55,000 | $0.00 | $0.00 | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.